| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
101,580,000 |
| Market
Cap: |
967.04(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.28 - $27.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 11.4 |
| Insider 6 Months : 11.4 |
| Insider 3/6 Months : 23.2 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
100,000 |
100,000 |
100,000 |
100,000 |
| Total Buy Value |
$1,003,000 |
$1,003,000 |
$1,003,000 |
$1,003,000 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
1,902 |
15,983 |
88,020 |
145,372 |
| Total Sell Value |
$33,057 |
$201,683 |
$1,067,078 |
$2,735,393 |
| Total People Sold |
2 |
5 |
11 |
13 |
| Total Sell Transactions |
2 |
7 |
19 |
32 |
| End Date |
2025-08-10 |
2025-05-09 |
2024-11-08 |
2023-11-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schultes Birgit C |
EVP, Chief Scientific Officer |
• – – |
2025-10-01 |
4 |
S |
$17.38 |
$539 |
D/D |
(31) |
105,184 |
|
34% |
|
| Dube Michael P |
VP, Chief Accounting Officer |
• – – |
2025-10-01 |
4 |
S |
$17.38 |
$32,518 |
D/D |
(1,871) |
55,266 |
|
34% |
|
| Chase William J |
|
– • – |
2025-08-20 |
4 |
B |
$10.03 |
$1,003,000 |
D/D |
100,000 |
134,693 |
0.01 |
21% |
|
| Dulac Edward J Iii |
EVP, Chief Financial Officer |
• – – |
2025-07-23 |
4 |
S |
$14.02 |
$104,617 |
D/D |
(7,462) |
106,062 |
|
13% |
|
| Dube Michael P |
VP, Chief Accounting Officer |
• – – |
2025-07-02 |
4 |
S |
$9.95 |
$24,905 |
D/D |
(2,503) |
57,137 |
|
-15% |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2025-07-01 |
4 |
S |
$9.82 |
$10,036 |
D/D |
(1,022) |
95,369 |
|
-25% |
|
| Goodman Jesse |
|
– • – |
2025-07-01 |
4 |
AS |
$9.23 |
$14,279 |
D/D |
(1,547) |
24,359 |
|
25% |
|
| Goodman Jesse |
|
– • – |
2025-06-30 |
4 |
AS |
$9.56 |
$14,789 |
D/D |
(1,547) |
25,906 |
|
45% |
|
| Keresty Georgia |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
31,883 |
|
- |
|
| Bhanji Muna |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
27,203 |
|
- |
|
| Goodman Jesse |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
27,453 |
|
- |
|
| Verwiel Frank |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
25,948 |
|
- |
|
| Chase William J |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
34,693 |
|
- |
|
| Goff Brian |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
23,409 |
|
- |
|
| Cohen Fred E |
|
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
57,453 |
|
- |
|
| Bhanji Muna |
|
– • – |
2025-04-29 |
4 |
AS |
$8.50 |
$2,253 |
D/D |
(265) |
19,203 |
|
44% |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2025-03-04 |
4 |
S |
$8.99 |
$6,104 |
D/D |
(679) |
95,369 |
|
-31% |
|
| Basta James |
EVP, General Counsel |
• – – |
2025-03-04 |
4 |
S |
$8.99 |
$23,122 |
D/D |
(2,572) |
111,925 |
|
-31% |
|
| Leonard John M. |
President and CEO |
• • – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
136,000 |
1,077,115 |
|
- |
|
| Dube Michael P |
VP, Chief Accounting Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
59,640 |
|
- |
|
| Dulac Edward J Iii |
EVP, Chief Financial Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
47,200 |
113,524 |
|
- |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
96,048 |
|
- |
|
| Lebwohl David |
EVP, Chief Medical Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
43,200 |
130,866 |
|
- |
|
| Schultes Birgit C |
EVP, Chief Scientific Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
37,600 |
105,215 |
|
- |
|
| Basta James |
EVP, General Counsel |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
114,497 |
|
- |
|
295 Records found
|
|
Page 1 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
2.80 (22.73%) 
